Targeted Alpha Therapeutics
Lansing
About Targeted Alpha Therapeutics
Targeted Alpha Therapeutics produces alpha-emitting radionuclides such as Actinium-225 and Astatine-211 for targeted alpha therapy. The company uses cyclotron technology to manufacture these isotopes under cGMP standards, enabling preclinical research, drug development, and clinical applications. Its operations support the advancement of precision oncology by supplying therapeutic isotopes to biotech firms and medical institutions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: Seed
- Last round: Pre-Seed (Jul 2023)
Canonical: https://fsome.com/organization/targeted-alpha-therapeutics-3538698 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.